An update of the pivotal EpiSTOP trial was presented by Professor Sergiusz Jóźwiak of the Medical University of Warsaw in Warsaw, Poland, at AES 2018.
According to Prof. Jóźwiak, TSC affects about 1 in 6000 newborns, and most will develop epilepsy. Patients may have normal EEG findings initially, but very subtle focus seizures may appear around the age of 3 months that are “very easy to overlook,” said Prof. Jóźwiak. In some patients, these seizures develop into overt infantile spasms associated with poor mental and behavioral outcomes.